Nikpanah, Moozhan
Kim, Lauren
Mirmomen, S. Mojdeh
Symons, Rolf
Papageorgiou, Ioannis
Gahl, William A.
O’Brien, Kevin
Estrada-Veras, Juvianee I.
Malayeri, Ashkan A.
Funding for this research was provided by:
National Human Genome Research Institute
National Heart, Lung, and Blood Institute
National Cancer Institute
NIH Clinical Center
Article History
Received: 4 October 2017
Revised: 4 January 2018
Accepted: 12 January 2018
First Online: 19 March 2018
Compliance with ethical standards
:
: The scientific guarantor of this publication is Ashkan A. Malayeri.
: The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.
: One of the authors (Rolf Symons, M.D.) has significant statistical expertise.
: Written informed consent was obtained from all subjects (patients) in this study.
: Institutional review board approval was obtained from institutional review board at the National Human Genome Research Institute (NHGRI), Bethesda, MD, USA.
: Some study subjects or cohorts have been previously reported in the paper titled “The clinical spectrum of Erdheim–Chester disease: an observational cohort study” by Estrada-Veras et al.
: • This was an observational prospective single-centre study.